Singapore markets close in 33 minutes
  • Straits Times Index

    3,254.29
    -17.28 (-0.53%)
     
  • Nikkei

    26,170.30
    -841.03 (-3.11%)
     
  • Hang Seng

    23,807.00
    -482.90 (-1.99%)
     
  • FTSE 100

    7,422.09
    -47.69 (-0.64%)
     
  • BTC-USD

    36,159.38
    -1,397.22 (-3.72%)
     
  • CMC Crypto 200

    823.98
    -31.83 (-3.72%)
     
  • S&P 500

    4,349.93
    -6.52 (-0.15%)
     
  • Dow

    34,168.09
    -129.61 (-0.38%)
     
  • Nasdaq

    13,542.12
    +2.82 (+0.02%)
     
  • Gold

    1,809.20
    -20.50 (-1.12%)
     
  • Crude Oil

    87.22
    -0.13 (-0.15%)
     
  • 10-Yr Bond

    1.8480
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,513.49
    -2.27 (-0.15%)
     
  • Jakarta Composite Index

    6,611.16
    +10.34 (+0.16%)
     
  • PSE Index

    7,273.52
    +19.91 (+0.27%)
     

Apellis Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • APLS

WALTHAM, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format.

The conference event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, we aim to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. For more information, please visit www.apellis.com.

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting